1. Introduction {#sec1}
===============

Among the neuropeptide Y (NPY) receptors, designated Y~1~R, Y~2~R, Y~4~R, and Y~5~R,^[@ref1]^ the Y~4~R plays a special role because it preferentially binds pancreatic polypeptide.^[@ref2]^ Compared to the Y~1~R, Y~2~R, and Y~5~R subtypes, fewer ligands by far (e.g., see [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) have been reported for the Y~4~R, in particular, high-affinity Y~4~R antagonists are still lacking.^[@ref3]−[@ref6]^

![Amino acid sequence of human PP and structures of the described NPY Y~4~R agonists **1**--**3** and the Y~1~R/Y~4~R antagonist UR-MK188 (**4**).](ao-2017-004517_0001){#fig1}

Y~4~R agonists are considered to be potential antiobesity agents.^[@ref7],[@ref8]^ The diastereomeric mixture of the cross-linked ("dimeric") pentapeptide **1** (BVD-74D), a mimic of the C-terminus of pancreatic polypeptide, was described as a high-affinity Y~4~R agonist,^[@ref4]^ having an effect on food intake in mice.^[@ref9]^ As reported previously, (2*R*,7*R*)-**1** (note: in the following, positions 2 and 7 refer to the stereo centers in the 2,7-diaminosuberic acid moiety) was, by a factor of 3--10, more potent than (2*S*,7*S*)-**1**, depending on the type of assay.^[@ref10],[@ref11]^ Even though Y~4~R agonists should have higher clinical potential, antagonists are of interest as well, in particular, as pharmacological tools. The pentapeptide **3**,^[@ref6]^ a Y~4~R agonist with an affinity in the two-digit nanomolar range (*K*~i~ = 50 nM), shares the same amino acid sequence with the peptide moieties of **1**. The incorporation of cyclic β-amino acids such as (1*R*,2*S*)-2-aminocyclopentane-1-carboxylic acid resulted in partial agonism.^[@ref6]^

To investigate the impact of backbone modifications in Y~4~R agonists on functional activity in more detail, additional analogues of (2*R*,7*R*)-**1**, **2**,^[@ref11]^ and **3** were prepared. Here, we report on the synthesis of Y~4~R ligands in which aza-amino acids or [d]{.smallcaps}-amino acids were introduced. The title compounds were characterized in binding and functional cellular assays with complementary readouts.

2. Results and Discussion {#sec2}
=========================

2.1. Chemistry {#sec2.1}
--------------

Aza-peptides contain at least one amino acid in which the α-carbon atom is replaced by nitrogen.^[@ref12]^ The semicarbazide substructure reduces conformational flexibility.^[@ref13],[@ref14]^ Several studies have revealed that the incorporation of aza-amino acids into bioactive peptides may result in a longer duration of action or higher potencies compared to the parent peptide.^[@ref15]−[@ref17]^ Aza-peptides can be prepared by the reaction of an N-protected, N′-substituted hydrazine with an isocyanate.^[@ref12]^ However, the synthesis of aza-peptides on a solid phase is compromised by an intramolecular side-reaction of resin-bound isocyanates that results in the formation of hydantoins ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A), lowering the yields of the target compounds and requiring time-consuming purification.^[@ref18]^ To circumvent hydantoin formation, *N*-Fmoc-aza^1^-dipeptides were prepared from N-protected, N′-substituted hydrazines and benzyl ester-protected amino acids, followed by hydrogenolytic debenzylation in solution ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B).^[@ref19]^

![Synthesis of aza-peptides on a solid phase (A) or in solution (B).](ao-2017-004517_0002){#fig2}

Two different Fmoc-protected hydrazines were synthesized to mimic the side chains of Orn or Leu, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). 3-Aminopropan-1-ol was Boc-protected and subsequently oxidized under Parikh--Döring conditions using dimethyl sulfoxide (DMSO) as an oxidant to form the aldehyde **7**. Condensation of (9*H*-fluoren-9-yl)methyl hydrazinecarboxylate **8** and the aldehyde **7** or isobutyric aldehyde resulted in hydrazones **9** and **11**. Subsequent reduction using sodium cyanotrihydridoborate gave access to the substituted hydrazines **10** and **12**.

![Synthesis of the Hydrazines **10** and **12**\
Reagents and conditions: (a) Boc~2~O, Na~2~CO~3~, tetrahydrofuran (THF), 0 °C, 10 min, followed by room temperature (rt), 14 h; (b) sulfur trioxide pyridine complex, DMSO, triethylamine (TEA), CH~2~Cl~2~, 0 °C, 1 h, followed by rt, 3 h; (c) Fmoc-Cl, MeCN/H~2~O (1:1), 0 °C, 10 min, followed by rt, 12 h; (d) **7**, CH~2~Cl~2~, 14 h; (e) isobutyraldehyde, CH~2~Cl~2~, 50 h; (f) sodium cyanotrihydridoborate, CH~2~Cl~2~/MeOH (4:3), 2 M HCl (pH 2--3), rt, 2--6 h.](ao-2017-004517_0011){#sch1}

The benzyl ester-protected amino acids **14**--**16** were treated with triphosgene to give the respective isocyanates in situ ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Without purification, the isocyanates were treated with hydrazines **10** and **12** affording the benzyl-protected *N*-Fmoc-aza^1^-dipeptides in yields \>70%. Subsequent ester cleavage by hydrogenation gave access to the *N*-Fmoc-aza^1^-dipeptides Fmoc-aza-Leu-Arg(Pbf)-OH (**17**), Fmoc-aza-Orn(Boc)-Tyr(*t*Bu)-OH (**18**), and Fmoc-aza-Orn(Boc)-Leu-OH (**19**). The dipeptides **17**--**19** were employed in solid phase synthesis under the same conditions as those for the standard Fmoc-protected amino acids, resulting in quantitative coupling efficiencies.

![Synthesis of the *N*-Fmoc-aza^1^-dipeptides **17**--**19**\
Reagents and conditions: (a) Benzyl alcohol, 4-dimethylaminopyridine (4-DMAP), dicyclohexylcarbodiimide (DCC), CH~2~Cl~2~, rt, 14 h, followed by DEA/CH~2~Cl~2~ (1:8), rt; (b) triphosgene, *N*,*N*-diisopropylethylamine (DIPEA), CH~2~Cl~2~, rt, 90 min, followed by Pd/C, H~2~, MeOH, rt, 1 h.](ao-2017-004517_0012){#sch2}

To optimize the coupling of a resin-bound aza^1^-peptide, the model peptide H-Ala-aza-Leu-Arg(Pbf)-NH~2~ (**20**) was synthesized under various conditions ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). When 3-\[bis(dimethylamino)methyliumyl\]-3*H*-benzotriazol-1-oxide hexafluorophosphate/hydroxybenzotriazole (HBTU/HOBt) was used as coupling reagent at 35 °C, only 5--10% of the desired products were formed. The same holds for the application of the succinimidyl ester, Fmoc-Ala-OSu. The coupling efficiency was increased to approximately 50% when the 7-aza-benzotriazole derivative HATU was used as coupling reagent. The best results (\>50% coupling efficiency) were achieved by in situ activation of Fmoc-Ala-OH to the corresponding acyl chloride using triphosgene in THF. Surprisingly, when CH~2~Cl~2~ was used as a solvent instead of THF, only minor amounts of **20** were detected.

![Incorporation of aza-Leu into the Model Peptide **20** via SPPS\
Reagents and conditions: (a) SPPS (Fmoc strategy), **17**/HBTU/HOBt/DIPEA (3/3/3/6 equiv), solvent DMF, 35 °C, 14 h; Fmoc deprotection was carried out with 20% piperidine in DMF/*N*-methyl-2-pyrrolidone (NMP) (8:2), rt, 2 × 10 min; (b) variation of the conditions according to the table; Fmoc deprotection as under (a); (c) Fmoc deprotection, followed by CH~2~Cl~2~/trifluoroacetic acid (TFA) (97:3), 10 × 6 min.](ao-2017-004517_0013){#sch3}

The dimeric aza-peptide (2*R*,7*R*)-**26**, an aza-Leu analogue of (2*R*,7*R*)-**1**, was prepared from the protected pentapeptide **21** and the diacid (*R*,*R*)-**24** ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). For the preparation of the aza-peptides **27**--**31**, octanedioic acid disuccinimidyl ester (**25**) was used for cross-linking. Cross-linking of **21** with **25** yielded the dimeric aza-peptide **27**, an aza-Leu analogue of **2**. Dimerization of the protected peptides **22** and **23** resulted in the aza-peptides **28** and **30** containing ornithine instead of arginine. Subsequently, guanidinylation was performed with *N*,*N*′-di-Boc-1*H*-pyrazole-1-carboxamidine resulting in **29** and **31**, which were aza-Arg-containing analogues of **2**.

![Synthesis of "Homodimeric" Aza-Peptides **26**--**31**\
Reagents and conditions: (a) SPPS (Fmoc strategy), Fmoc-aa/HBTU/HOBt/DIPEA (5/5/5/10 equiv), solvent DMF/NMP (8:2), "double" coupling at rt, 60 min or dipeptide (**17**, **18**, or **19**)/HBTU/HOBt/DIPEA (3/3/3/6), solvent: DMF, 35 °C, 14 h; Fmoc deprotection as under (a) in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}; (b) triphosgene, DIPEA, THF, 35 °C, 14 h; Fmoc deprotection as under (a) in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}; (c) CH~2~Cl~2~/TFA (97:3), 10 × 6 min; (d) HBTU, HOBt, DIPEA, anhydrous DMF, 35 °C, 16 h; (e) 1 equiv of **25** in 1% DIPEA in anhydrous DMF, followed by 2.5 equiv of **21**, **22**, or **23**, 35 °C, 16 h; (f) TFA/H~2~O (95:5), rt, 2.5 h; (g) *N*,*N*'-di-Boc-1*H*-pyrazole-1-carboxamidine, DMF, DIPEA, rt, 4 h; Boc-deprotection, TFA/CH~2~Cl~2~/H~2~O (10/10/1), rt, 3 h.](ao-2017-004517_0014){#sch4}

Very recently, we reported that the replacement of Arg^2^ with the *N*^ω^-carbamoylated arginine **32** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}) in one of the pentapeptide chains of **2** led to increased Y~4~R affinity.^[@ref11]^ Similarly, **32** was used for the preparation of peptides **33**--**42** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), which are analogues of the pentapeptide **3**, on an Fmoc-Sieber-PS resin by manual SPPS according to the Fmoc strategy.

![Structure of the *N*^ω^-carbamoylated arginine building block **32**.^[@ref20]^](ao-2017-004517_0003){#fig3}

![Primary structures of all investigated peptides.](ao-2017-004517_0004){#fig4}

Finally, the applicability of **32** to the preparation of cyclic peptides via head-to-side-chain cyclization was investigated. Cyclic peptides are structurally more constrained than their linear counterparts and can mimic secondary structural elements of native peptides or proteins. Additionally, cyclic peptides are less prone to enzymatic degradation. The formation of head-to-tail cyclic peptides is often compromised by rather rigid backbones. However, the side-chain of **32** is very flexible, facilitating an approximation of the activated C-terminus and the terminal amino group. The hexapeptide **43** was prepared on an H-[l]{.smallcaps}-Tyr(*t*Bu)-2CT resin followed by global side-chain deprotection ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). Cyclization was achieved at a peptide concentration of 1 mM using benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as coupling reagent. Under these conditions, the formation of peptide dimers was not observed.

![Synthesis of the Head-to-Side-Chain Cyclic Peptide **43**\
Reagents and conditions: (a) SPPS (Fmoc strategy), Fmoc-aa/HBTU/HOBt/DIPEA (5/5/5/10 equiv), solvent DMF/NMP (8:2), double coupling at rt, 60 min or **32**/HBTU/HOBt/DIPEA (3/3/3/6), solvent: DMF, 35 °C, 14 h; Fmoc deprotection as under (a) in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}; (b) CH~2~Cl~2~/TFA (97:3), 10 × 6 min; (c) TFA/H~2~O (95:5), rt, 2.5 h; (d) PyBOP, HOBt, DIPEA, DMF, rt, 24 h.](ao-2017-004517_0015){#sch5}

2.2. Competition Binding Studies at NPY Receptor Subtypes. Y~4~R Binding {#sec2.2}
------------------------------------------------------------------------

The *K*~i~ values of all of the target compounds were determined in competition binding studies on live cells expressing Y~4~R (CHO-hY~4~R-G~qi5~-mtAEQ cells) using the radioligand \[^3^H\]UR-KK193 (**45**, [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}).^[@ref11]^ The affinities of the aza-peptides **27** (*K*~i~ = 134 nM), **29** (*K*~i~ = 52.7 nM), and **31** (*K*~i~ = 113 nM) were lower than the affinity of the respective reference compound **2** (*K*~i~ = 3.5 nM). (*R*,*R*)-2,7-Diaminosuberic acid was superior to octanedioic acid as a linker in the dimeric aza-peptides (cf. (2*R*,7*R*)-**26**: *K*~i~ = 30.8 nM), as in the case of peptide **1** compared to **2**. The aza-Orn precursors of **29** and **31**, compounds **28** (*K*~i~ = 130 nM) and **30** (*K*~i~ = 385 nM), bind to the Y~4~R as well, though with lower affinities compared to their aza-Arg counterparts.

![Structures of the Y~4~R radioligand \[^3^H\]UR-KK193 (**45**) and the Y~1~R radioligand \[^3^H\]UR-MK136 (**46**).](ao-2017-004517_0005){#fig5}

![Competition binding performed with the radioligand **45** at CHO-hY~4~R-G~qi5~-mtAEQ cells. (A--C) Displacement of **45** (*K*~d~ = 0.67 nM, *c* = 0.6 nM). Data represent mean values ± SEM of at least three independent experiments, each performed in triplicate.](ao-2017-004517_0006){#fig6}

###### Binding Data at NPY Receptor Subtypes

                       Y~1~R                                 Y~2~R                                    Y~4~R                                  Y~5~R
  -------------------- ------------------------------------- ---------------------------------------- -------------------------------------- ----------------------------------------
  hPP                  440[e](#t1fn5){ref-type="table-fn"}   \>5000[e](#t1fn5){ref-type="table-fn"}   0.65[f](#t1fn6){ref-type="table-fn"}   17[e](#t1fn5){ref-type="table-fn"}
  (2*R*,7*R*)-**1**    440[f](#t1fn6){ref-type="table-fn"}   830[f](#t1fn6){ref-type="table-fn"}      0.45[f](#t1fn6){ref-type="table-fn"}   1500[f](#t1fn6){ref-type="table-fn"}
  **2**                720[f](#t1fn6){ref-type="table-fn"}   1700[f](#t1fn6){ref-type="table-fn"}     3.5[f](#t1fn6){ref-type="table-fn"}    280[f](#t1fn6){ref-type="table-fn"}
  **3**                \>5000                                \>5000                                   337 ± 110                              \>5000
  **4**                24[g](#t1fn7){ref-type="table-fn"}    920[g](#t1fn7){ref-type="table-fn"}      660[f](#t1fn6){ref-type="table-fn"}    \>5000[g](#t1fn7){ref-type="table-fn"}
  (2*R*,7*R*)-**26**   1840 ± 380                            \>5000                                   30.8 ± 7.5                             \>5000
  **27**               574 ± 49                              \>5000                                   134 ± 20                               2700 ± 490
  **28**               n.d.                                  n.d.                                     130 ± 39                               n.d.
  **29**               3730 ± 350                            \>5000                                   52.7 ± 7.1                             3560 ± 440
  **30**               n.d.                                  n.d.                                     385 ± 127                              n.d.
  **31**               53 ± 12                               3270 ± 870                               113 ± 14                               2100 ± 240
  **33**               589 ± 120                             \>5000                                   56.9 ± 5.3                             3440 ± 210
  **34**               \>5000                                \>5000                                   19.5 ± 2.6                             \>5000
  **35**               4830 ± 1400                           \>5000                                   2.87 ± 0.78                            \>5000
  **36**               1180 ± 380                            \>5000                                   3.43 ± 1.3                             \>5000
  **37**               1120 ± 270                            \>5000                                   501 ± 200                              \>5000
  **38**               \>5000                                \>5000                                   724 ± 140                              \>5000
  **39**               \>5000                                \>5000                                   568 ± 76                               \>5000
  **40**               \>5000                                \>5000                                   248 ± 23                               \>5000
  **41**               \>5000                                \>5000                                   10.4 ± 3.3                             \>5000
  **42**               \>5000                                \>5000                                   40.5± 15                               \>5000
  **43**               \>5000                                \>5000                                   \>5000                                 \>5000
  **44**               \>5000                                \>5000                                   1650 ± 290                             \>5000

Radioligand competition binding assay with **46**([@ref22]) (*K*~d~ = 6.2 nM, *c* = 4 nM) using MCF-7-hY~1~ cells.^[@ref23]^

Radioligand competition binding assay with \[^3^H\]propionyl-pNPY^[@ref24]^ (*K*~d~ = 1.4 nM, *c* = 1 nM) using CHO-hY~2~-G~qi5~-mtAEQ cells.^[@ref25]^

Radioligand competition binding assay with **45**([@ref11]) (*K*~d~ = 0.67 nM, *c* = 0.6 nM) using CHO-hY~4~R-G~qi5~-mtAEQ cells.^[@ref26]^

Radioligand competition binding assay with \[^3^H\]propionyl-pNPY (*K*~d~ = 4.83 nM, *c* = 4 nM) using HEC-1b hY~5~R cells.^[@ref27]^

*K*~i~ value reported by Berlicki et al.^[@ref6]^

*K*~i~ value reported by Kuhn et al.^[@ref11]^

*K*~i~ value reported by Keller et al.^[@ref5]^ Presented are mean values ± SEM from at least three independent experiments (performed in triplicate). n.d.: not determined.

Among the structural modifications of pentapeptide **3**, replacement of the N-terminal acetic acid with octanoic acid (compound **33**) resulted in an increase in Y~4~R affinity by a factor of almost six. The replacement of Arg^2^ in **3** with the carbamoylated arginine **32** was even more favorable: the affinity of **34** (*K*~i~ = 19.5 nM) was 17-fold higher than the affinity of its parent compound **3**. Extension of the N-terminus by an additional arginine led to a further increase in affinity: the *K*~i~ value of compound **35** was in the single-digit nanomolar range (*K*~i~ = 2.87 nM). Up to now, comparable binding data were achieved only in the case of cross-linked or significantly longer linear peptides. The extension of the N-terminus of **3** by an additional arginine alone had almost the same impact on Y~4~R affinity, that is, **36** (*K*~i~ = 3.43 nM) showed nearly the same affinity as peptide **35**. Interestingly, the replacement of the arginine adjacent to the C-terminus with the modified arginine building block **32** was not tolerated (**37**: *K*~i~ = 501 nM).

Following the structural optimization of **3**, a [d]{.smallcaps}-amino acid scan was performed with the hexapeptide **35**. Whereas replacement of Arg^1^ or Tyr^2^ with [d]{.smallcaps}-Arg or [d]{.smallcaps}-Tyr, respectively, was tolerated (cf. **41**, **42**), replacement of Leu^4^, Arg^5^, or Tyr^6^ by the corresponding [d]{.smallcaps}-amino acid led to a marked decrease in Y~4~R affinity (cf. **38**--**40**).

Previous studies revealed that C-terminal amidation is crucial for Y~4~R binding of the endogenous ligand hPP.^[@ref21]^ Similarly, the affinity of the carboxylic acid **43** (IC~50~ \> 5000 nM) was much lower than the affinity of the amide **35**. Cyclization of **43** resulted in an increase in Y~4~R affinity. However, the cyclic peptide **44** (*K*~i~ = 1650 nM) was only a weak binder compared to the linear analogue **35**.

2.3. NPY Receptor Subtype Selectivity {#sec2.3}
-------------------------------------

*K*~i~ values of all of the target compounds were also determined at the Y~1~, Y~2~, and Y~5~ receptors using the radioligands \[^3^H\]propionyl-pNPY (Y~2~R and Y~5~R) or \[^3^H\]UR-MK136 (**46**, Y~1~R, [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). Neither the linear peptides **34**--**43** nor the cyclic peptide **44** displayed remarkable affinity to the Y~1~, Y~2~, or Y~5~ receptors. Having a more than 1000-fold selectivity for the Y~4~R over the other NPY receptors, peptide **35** proved to be superior to (2*R*,7*R*)-**1** and **2**. Only the pentapeptide **33** bound to the Y~1~R with a *K*~i~ value in the submicromolar range (*K*~i~ (Y~1~R) = 589 nM), that is, the lipophilic N-terminal octanoyl residue is disadvantageous with respect to Y~4~R selectivity.

The cross-linked aza-peptides (2*R*,7*R*)-**26**, **27**, and **29** displayed only low Y~1~R, Y~2~R, and Y~5~R affinities, whereas the affinity of **31** (*K*~i~ = 53 nM) at the Y~1~R was markedly higher than that of the peptide analogue **2**. In a Fura-2 Ca^2+^ assay on human erythroleukemia (HEL) cells, **31** revealed Y~1~R antagonism ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}) with a *K*~b~ value of 11.5 nM.

![Y~1~R antagonism of **31**. Inhibition of pNPY (*c* = 10 nM, EC~50~ = 0.87 nM)-induced intracellular Ca^2+^ mobilization in HEL cells by **31** (*K*~b~ = 11.5 ± 1.1 nM), determined in a Fura-2 assay. Mean ± SEM from three independent experiments.](ao-2017-004517_0007){#fig7}

2.4. Functional Studies at the Y~4~R {#sec2.4}
------------------------------------

The target compounds were investigated for Y~4~R agonism and antagonism in an aequorin Ca^2+^ assay as well as β-arrestin 1 and β-arrestin 2 recruitment assays on genetically engineered CHO or HEK293T cells, respectively (for data see [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, [Figures [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}--[10](#fig10){ref-type="fig"}, [SI Figures 1--8](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00451/suppl_file/ao7b00451_si_001.pdf)).

![Y~4~R agonism of (2*R*,7*R*)-**1**, **33**--**36**, **41**, and **42** determined in a calcium (aequorin) assay, a β-arrestin recruitment assay, and a luciferase reporter gene assay. (A, B) Induced intracellular Ca^2+^ mobilization in CHO-hY~4~R-mtAEQ-G~qi5~ cells. (C, D) Induced β-arrestin 1 recruitment in HEK293T-ARRB1-Y~4~R cells. (E, F) Induced β-arrestin 2 recruitment in HEK293T-ARRB2-Y~4~R cells. Data points shown for (A)--(F) are the mean ± SEM of at least three independent experiments performed in triplicate.](ao-2017-004517_0008){#fig8}

![Y~4~R antagonism of (2*R*,7*R*)-**26** and **27** determined in a calcium (aequorin) assay, a β-arrestin recruitment assay, and a luciferase reporter gene assay. (A) Inhibition of hPP (EC~50~ = 9.7 nM, *c* = 100 nM)-induced Ca^2+^ mobilization in CHO-hY~4~R-mtAEQ-G~qi5~ cells. (B) Inhibition of hPP (EC~50~ (Arr1) = 3.54 nM, EC~50~ (Arr2) = 2.74 nM, *c* = 3 nM)-induced β-arrestin 1,2 recruitment in HEK293T-ARRB1-Y~4~R cells (β-arrestin 1, solid lines) and HEK293T-ARRB2-Y~4~R cells (β-arrestin 2, dashed lines). (C) Inhibition of forskolin-stimulated (2 μM) luciferase activity (corresponding to 100%) in hY~4~R expressing HEK293 cells with the maximum inhibitory effect of the endogenous ligand hPP, which was set to 0% luciferase activity and corresponds to full agonism (α = 1.0). Data points shown for (A)--(C) are the mean ± SEM of at least three independent experiments performed in triplicate.](ao-2017-004517_0009){#fig9}

![Y~4~R functional activity of **38** and **44** determined in a calcium (aequorin) assay and a β-arrestin recruitment assay. (A) Inhibition of hPP (EC~50~ = 9.7 nM, *c* = 100 nM)-induced intracellular Ca^2+^ mobilization in CHO-hY~4~R-mtAEQ-G~qi5~ cells. (B) Inhibition of hPP (EC~50~ (Arr1) = 3.54 nM, EC~50~ (Arr2) = 2.74 nM, *c* = 3 nM)-induced β-arrestin 1,2 recruitment in HEK293T-ARRB1-Y~4~R cells (β-arrestin 1, solid lines) and HEK293T-ARRB2-Y~4~R cells (β-arrestin 2, dashed lines). Data points shown for (A) and (B) are the mean ± SEM of at least three independent experiments performed in triplicate. Note: Inhibition of hPP-induced response appears incomplete, however, concentrations of antagonists higher than those given in the curves could not be applied due to a shortage of the test compounds. There was no intrinsic activity of both compounds in the respective assays when performed in the agonist mode ([SI Figures 3, 5, and 7](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00451/suppl_file/ao7b00451_si_001.pdf)).](ao-2017-004517_0010){#fig10}

###### NPY Y~4~R Agonist Potencies (EC~50~) and Intrinsic Activities (α) or Antagonism (IC~50~ Values)

                                                       aequorin assay[a](#t2fn1){ref-type="table-fn"}          β-arrestin 1 assay[b](#t2fn2){ref-type="table-fn"}          β-arrestin 2 assay[b](#t2fn2){ref-type="table-fn"}    
  ---------------------------------------------------- ------------------------------------------------ ------ ---------------------------------------------------- ------ ---------------------------------------------------- ------
  hPP                                                  9.7[c](#t2fn3){ref-type="table-fn"}              1      3.54 ± 0.59                                          1      2.74 ± 0.23                                          1
  (2*R*,7*R*)-**1**                                    6.9[c](#t2fn3){ref-type="table-fn"}              0.62   40.4 ± 11                                            0.54   31.8 ± 12                                            0.58
  **2**                                                49[c](#t2fn3){ref-type="table-fn"}               0.73   n.d.                                                 n.d.   n.d.                                                 n.d.
  **3**                                                6390 ± 450                                       0.55   n.d.                                                 n.d.   n.d.                                                 n.d.
  **4**                                                *226*[d](#t2fn4){ref-type="table-fn"}            n.a.   *187 ± 72*                                           n.a.   *202 ± 78*                                           n.a.
  (2*R*,7*R*)-**26**[e](#t2fn5){ref-type="table-fn"}   *388 ± 51*                                       n.a.   *5430 ± 350*                                         n.a.   *1320 ± 230*                                         n.a.
  **27**[f](#t2fn6){ref-type="table-fn"}               *1430 ± 290*                                     n.a.   *1090 ± 350*                                         n.a.   *712 ± 87*                                           n.a.
  **29**                                               542 ± 110                                        0.07   875 ± 260                                            0.09   473 ±65                                              0.12
  *572 ± 59*                                           n.a.                                             n.d.   n.d.                                                 n.d.   n.d.                                                 
  **31**                                               *1340 ± 530*                                     n.a.   n.d.                                                 n.d.   n.d.                                                 n.d.
  **33**                                               2050 ± 84                                        0.44   2200 ± 130                                           0.56   1790 ± 1070                                          0.61
  **34**                                               1460 ± 83                                        0.61   1070 ± 520                                           0.62   568 ± 120                                            0.60
  **35**                                               187 ± 23                                         0.58   144 ± 28                                             0.48   124.1 ± 24                                           0.55
  **36**                                               303 ± 68                                         0.78   187 ± 40                                             0.51   140 ± 45                                             0.54
  **37**                                               *9580 ± 2000*                                    n.a.   *6640 ± 780*                                         n.a.   *8050 ± 120*                                         n.a.
  **38**                                               *18 800 ± 6500*                                  n.a.   *1310 ± 390*                                         n.a.   *1120 ± 250*                                         n.a.
  **39**                                               *8340 ± 2900*                                    n.a.   n.d.                                                 n.d.   n.d.                                                 n.d.
  **40**                                               *6000 ± 2600*                                    n.a.   n.d.                                                 n.d.   n.d.                                                 n.d.
  **41**                                               608 ± 140                                        0.61   2050 ± 780                                           0.46   710 ± 200                                            0.49
  **42**                                               756 ± 230                                        0.63   2160 ± 600                                           0.45   624 ± 150                                            0.56
  **44**                                               *12 400 ± 5500*                                  n.a.   *5390 ± 1630*                                        n.a.   *3940 ± 660*                                         n.a.

Aequorin calcium mobilization assay on CHO-hY~4~-G~qi5~-mtAEQ cells.^[@ref26]^ Antagonism (IC~50~ values given in italics) was determined in the presence of 100 nM hPP (EC~50~ = 9.7 nM).

β-Arrestin 1,2 recruitment assay on HEK293T cells stably expressing the Y~4~R and ARRB1 or ARRB2. Antagonism (IC~50~ values given in italics) was determined in the presence of 3 nM hPP (EC~50~ (ARRB1) = 3.54 nM; EC~50~ (ARRB2) = 2.74 nM).

EC~50~ value reported by Kuhn et al.^[@ref11]^

Reported as *K*~b~ = 20 nM by Keller et al.^[@ref5]^

Y~4~R agonism on HEK293-hY~4~R-CRE Luc cells (luciferase reporter gene assay): EC~50~ = 176 ± 50 nM, α = 0.81.

Y~4~R agonism on HEK293-hY~4~R-CRE Luc cells (luciferase reporter gene assay): EC~50~ = 220 ± 73 nM, α = 0.75. Presented are mean values ± SEM from at least three independent experiments (performed in triplicate). n.a.: not applicable; n.d.: not determined.

2.5. Y~4~R Agonism {#sec2.5}
------------------

(2*R*,7*R*)-**1** was a partial agonist in both the Ca^2+^ assay and the β-arrestin recruitment assays (α = 0.62, (Ca^2+^ assay), α = 0.54 (β-arrestin 1) or 0.58 (β-arrestin 2), [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}A,C,E). The pentapeptides **33** and **34**, and the hexapeptides **35** and **36**, were partial agonists achieving between 44 and 78% of the maximal response of hPP in both the calcium and the arrestin assay ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}). Y~4~R agonism was retained, though at a lower level, when [d]{.smallcaps}-amino acids were introduced into the N-terminal part of **35** (cf. **41**, **42**; [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}). In contrast, the aza-peptides (2*R*,7*R*)-**26**, **27**, and **31**, the carbamoyl-Arg modified peptides **37**--**40**, including those bearing [d]{.smallcaps}-amino acids in the C-terminus (**38**--**40**), as well as the cyclic hexapeptide **44** were devoid of Y~4~R agonism in the aequorin Ca^2+^ assay and the β-arrestin recruitment assays ([SI Figures 2--7](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00451/suppl_file/ao7b00451_si_001.pdf)). The aza-peptide **29** displayed weak partial agonism with extremely low intrinsic activity (EC~50~ = 542 nM, α = 0.07, (Ca^2+^ assay); EC~50~ = 875 nM, α = 0.09 (β-arrestin 1); EC~50~ = 473, α = 0.12 (β-arrestin 2)). Compounds (2*R*,7*R*)-**26** and **27** were also investigated for Y~4~R agonism in a luciferase reporter gene assay. Surprisingly, both aza-peptides displayed partial agonism in this assay (α = 0.81, EC~50~ = 176 nM ((2*R*,7*R*)-**26**), α = 0.75, EC~50~ = 220 nM (**27**)). Functional assays with distal readouts such as the luciferase reporter gene assay can reflect pronounced signal amplifications. It should be taken into account that the incubation period in the luciferase reporter gene assays was 4.5 h compared to 60 min for the arrestin assays and a few seconds in the case of the aequorin assay. Therefore, compounds displaying negligible agonistic activity in assays with proximal readouts may show much higher efficacies in reporter gene assays, as demonstrated, for example, for histamine H~4~ receptor ligands.^[@ref28]^ Likewise, (2*R*,7*R*)-**1**, a partial agonist in the Ca^2+^ assay and the arrestin assay, appeared as a full agonist in the luciferase assay.^[@ref11]^

2.6. Y~4~R Antagonism {#sec2.6}
---------------------

The incorporation of aza-amino acids into the cross-linked peptides (2*R*,7*R*)-**1** and **2** had an impact on the quality of action. The dimeric aza-peptides (2*R*,7*R*)-**26**, **27**, **29**, and **31** were able to suppress the response elicited by the endogenous ligand hPP ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}, [SI Figure 8](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00451/suppl_file/ao7b00451_si_001.pdf)). The introduction of [d]{.smallcaps}-amino acids into the C-terminal tripeptide of **35** led to Y~4~R antagonism, with compound **40**, in which Leu^4^ was replaced by [d]{.smallcaps}-Leu, displaying the strongest antagonism in the Ca^2+^ assay ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, [SI Figure 8](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00451/suppl_file/ao7b00451_si_001.pdf)). Compound **37**, in which Arg^5^ was replaced by the carbamoylated arginine **32**, and the cyclic hexapeptide **44** were identified as weak Y~4~R antagonists ([Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}, [SI Figure 1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00451/suppl_file/ao7b00451_si_001.pdf)).

In summary, modification of the C-terminal part of the monomeric and cross-linked peptide partial agonists by the introduction of aza-amino acids or [d]{.smallcaps}-amino acids as well as rigidization of the backbone by head-to-side-chain cyclization changed the quality of action to antagonism in the aequorin and β-arrestin assays. Unfortunately, these modifications went along with a decrease in Y~4~R affinity. The EC~50~ values of the reported Y~4~R partial agonists (**33**--**36**, **41**, **42**) were substantially higher than the *K*~i~ values. This effect was previously discussed and can be attributed to the presence or absence of sodium ions in the buffers.^[@ref11],[@ref29]^

3. Conclusions {#sec3}
==============

The affinity and potency of the Y~4~R partial agonist **3** was considerably increased by the replacement of Arg^2^ with the carbamoylated arginine **32** and the introduction of an additional arginine at the N-terminus. Several backbone modifications of the C-terminal tripeptide (e.g., the introduction of aza-amino acids or [d]{.smallcaps}-amino acids) of **35** as well as head-to-side-chain cyclization changed the quality of action of the linear or dimeric Y~4~R peptide ligands from partial agonism to antagonism. The resulting compounds displayed weaker Y~4~R antagonism than the reported Y~4~R antagonist **4**. However, due to their extremely facile synthetic accessibility, linear peptides derived from **35** containing [d]{.smallcaps}-amino acids (e.g., **40** (*K*~i~ = 248 nM)) are promising building blocks for further structural modifications and might pave the way for the development of peptide Y~4~R antagonists with increased affinity.

4. Experimental Section {#sec4}
=======================

4.1. Chemistry: General Conditions {#sec4.1}
----------------------------------

Chemicals and solvents were purchased from commercial suppliers and used without further purification unless otherwise indicated. DMF for peptide synthesis, NMP for peptide synthesis, 4-DMAP, sodium cyanotrihydroborate, and HOBt hydrate were from Acros Organics/Fisher Scientific (Nidderau, Germany). Fmoc-Sieber-PS resin (0.61 mmol/g), Fmoc-Arg(Pbf)-OH, Fmoc-Tyr(*t*Bu)-OH, H-[l]{.smallcaps}-Tyr(*t*Bu)-2CT resin (0.68 mmol/g), PyBOP, and HBTU were from Iris Biotech (Marktredwitz, Germany). MeCN for HPLC (gradient grade), Fmoc-Leu-OH, DCC, sulfur trioxide pyridine complex, hydrazine hydroxide, and methanol were from Merck (Darmstadt, Germany). Trifluoroacetic acid, TEA, triphosgene, Fmoc chloride, isobutyraldehyde, DEA, CH~2~Cl~2~, diethyl ether, and Triton X-100 were from Sigma-Aldrich (Deisenhofen, Germany); di-*tert*-butyl dicarbonate (\>97%) and 3-aminopropan-1-ol were from Alfa Aesar (Karlsruhe, Germany). DIPEA (99%) was from ABCR (Karlsruhe, Germany), and Fmoc-Ala-OSu was from Advanced Chemtech (Louisville, KY). Bovine serum albumin (BSA) and bacitracin were from Serva (Heidelberg, Germany) and coelenterazin h was obtained from Biotrend (Cologne, Germany). Human pancreatic polypeptide and porcine NPY were from Synpeptide (Shanghai, China). The synthesis of (2*R*,7*R*)-**1**,^[@ref11]^**3**,^[@ref6]^**4**,^[@ref5]^**24**,^[@ref11]^**25**,^[@ref30]^**32**,^[@ref20]^**45**,^[@ref11]^**46**,^[@ref22]^ and \[^3^H\]propionyl-pNPY^[@ref24]^ was previously described. Millipore water was used throughout for the preparation of buffers and HPLC eluents. Stock solutions of test compounds were prepared in Millipore water containing 0.1% TFA. Polypropylene reaction vessels (1.5 or 2 mL) with a screw cap (Süd-Laborbedarf, Gauting, Germany) were used for small scale reactions (e.g., the preparation of **44**) and for the storage of stock solutions. Thin-layer and column chromatography, NMR spectroscopy, mass spectrometry, preparative and analytical HPLC, as well as freeze-drying were performed as described previously.^[@ref11]^

4.2. Compound Characterization {#sec4.2}
------------------------------

Compounds were characterized as described previously.^[@ref11]^ Purities determined by reversed-phase high-performance liquid chromatography (RP-HPLC) were \>95%.

4.3. Chemistry: Experimental Protocols and Analytical Data. General Procedure for Solid Phase Peptide Synthesis {#sec4.3}
---------------------------------------------------------------------------------------------------------------

Peptides were synthesized by manual SPPS using the Fmoc strategy on an Fmoc-Sieber-PS resin or an H-[l]{.smallcaps}-Tyr(*t*Bu)-2CT resin (**43**) as described with minor modifications. Five milliliters Discardit II syringes (Becton Dickinson, Heidelberg, Germany) were equipped with 35 μm polyethylene frits (Roland Vetter Laborbedarf, Ammerbuch, Germany) and used as reaction vessels. For the coupling of standard [d]{.smallcaps}- or [l]{.smallcaps}-amino acid to the N-terminus of an amino acid or the amino group of the Fmoc-Sieber-PS resin, DMF/NMP (8:2) was used as solvent. Fmoc amino acids (5-fold excess) were preactivated with HBTU/HOBt/DIPEA (5/5/10 equiv) for 5 min and added to the resin. Double coupling at rt was performed for all standard amino acids for 45 min. The coupling of the arginine building block **32** and the dipeptides **17**--**19** (3-fold excess, preactivated with HBTU/HOBt/DIPEA (3/3/6 equiv)) was performed at 35 °C for 14 h ("single coupling") using anhydrous DMF as solvent. For the coupling of Fmoc amino acids to a resin-bound aza-amino acid, triphosgene was used as the coupling reagent. Triphosgene (1.75 equiv) was dissolved in anhydrous THF and cooled to 0 °C. A solution of Fmoc amino acid (5 equiv) and DIPEA (15 equiv) in anhydrous THF was added dropwise causing the formation of a white precipitate. After addition, stirring was continued for 5 min. The suspension was centrifuged and the supernatant was added to the resin. Coupling was performed at 35 °C for 12 h.

After coupling was completed, the resin was washed with DMF/NMP and treated with 20% piperidine in DMF/NMP (8:2) at rt (2×) for 10 min to remove the Fmoc group, followed by thorough washing of the resin.

### 4.3.1. Benzyl (*S*)-2-Amino-3-\[4-(*tert*-butoxy)phenyl\]propanoate (**15**) {#sec4.3.1}

Fmoc-Tyr(*t*Bu)-OH (2 g, 4.35 mmol, 1 equiv), 4-DMAP (53.2 mg, 0.1 equiv), and benzyl alcohol (1 mL, 2.2 equiv) were dissolved in CH~2~Cl~2~ (25 mL) and a solution of DCC (943 mg, 1.05 equiv) in CH~2~Cl~2~ (6 mL) was added dropwise under ice-cooling. The mixture was stirred at rt for 14 h. After completion of the reaction (monitored by thin-layer chromatography (TLC) (light petroleum/EtOAc 2:1): *R~f~* = 0.76), the mixture was filtered, and the filtrate was washed with 0.1 M HCl solution (30 mL) and brine (20 mL). The volume of the organic layer was adjusted to 70 mL with CH~2~Cl~2~, and diethylamine (12 mL) was added for removal of the Fmoc group. After all of the starting material had been consumed, the volatiles were removed on a rotary evaporator, and the residue was taken up in light petroleum/EtOAc (1:1, 10 mL) and subjected to column chromatography (eluent: light petroleum/EtOAc 1:1 → EtOAc/MeOH 4:1). The desired compound was obtained as a yellowish highly viscous oil (1.05 g, 73.7%). ^1^H NMR (300 MHz, DMSO-*d*~6~): δ (ppm) 1.26 (s, 9H), 1.80 (br s, 2H), 2.71--2.89 (m, 2H), 3.60 (t, 2H, *J* 6.9 Hz), 5.05 (s, 2H), 6.84 (d, 2H, *J* 8.5 Hz), 7.06 (d, 2H, *J* 8.4 Hz), 7.25--7.39 (m, 5H). ^13^C NMR (100.6 MHz, DMSO-*d*~6~): δ (ppm) 29.0 (3 carb), 56.4, 66.0, 78.0, 123.8 (2 carb), 128.40 (2 carb), 128.43, 128.8 (2 carb), 130.2 (2 carb), 132.9, 136.5, 153.9, 175.4. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for \[C~20~H~26~NO~3~\]^+^: 328.1907, found: 328.1915. C~20~H~25~NO~3~ (327.42).

### 4.3.2. *N*^2^-(2-{\[(9*H*-Fluoren-9-yl)methoxy\]carbonyl}-1-isobutylhydrazine-1-carbonyl)-*N*^ω^-\[(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl\]-[l]{.smallcaps}-arginine (**17**) {#sec4.3.2}

Triphosgene (152 mg, 0.4 equiv) was dissolved in CH~2~Cl~2~ (5 mL). A solution of **14** (145 mg, 0.442 mmol) and DIPEA (450 μL, 2 equiv) in CH~2~Cl~2~ (5 mL) was added dropwise under ice-cooling. The mixture was allowed to warm to ambient temperature under stirring for 30 min. A solution of **12** (200 mg, 1.1 equiv) in CH~2~Cl~2~ (2 mL) was added and stirring was continued for 90 min. The mixture was diluted with EtOAc (60 mL) and washed with water. The volatiles were removed under reduced pressure, the residue was taken up in EtOAc/hexane (2:1, 10 mL) and subjected to column chromatography (eluent: EtOAc/hexane (2:1)). The protected intermediate was dissolved in MeOH (10 mL), and Pd/C-catalyst (50 mg) was added. The mixture was stirred vigorously under hydrogen. After completion of the hydrogenation, the solids were removed by filtration through celite, the volume was reduced on a rotary evaporator. The desired compound was purified via column chromatography (eluent: CH~2~Cl~2~/MeOH (10:1) → CH~2~Cl~2~/MeOH (1:1) + 0.5% TFA). Removal of the volatiles under reduced pressure and by lyophilization afforded **14** as a white lyophilisate (370 mg, 88.5%). TLC (CH~2~Cl~2~/MeOH (10:0.6) + 1% AcOH): *R~f~* = 0.28. ^1^H NMR (400 MHz, methanol-*d*~4~): δ (ppm) 0.85 (s, 6H), 1.41 (s, 6H), 1.47--1.69 (m, 3H), 1.69--1.79 (m, 1H), 1.79--1.92 (m, 1H), 2.06 (s, 3H), 2.49 (s, 3H), 2.56 (s, 3H), 2.95 (s, 2H), 3.15 (s, 2H), 4.12--4.30 (m, 2H), 4.52 (s, 2H), 7.28 (t, 2H, *J* 7.3 Hz), 7.37 (t, 2H, *J* 7.3 Hz), 7.54--7.70 (m, 2H), 7.77 (d, 2H, *J* 7.5 Hz). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for \[C~39~H~51~N~6~O~8~S\]^+^: 763.3484, found: 763.3494. C~39~H~50~N~6~O~8~S (762.92).

### 4.3.3. (*S*)-5-({\[(9*H*-Fluoren-9-yl)methoxy\]carbonyl}amino)-2-\[4-(*tert*-butoxy)benzyl\]-12,12-dimethyl-4,10-dioxo-11-oxa-3,5,9-triazatridecanoic Acid (**18**) {#sec4.3.3}

Triphosgene (52.5 mg, 0.4 equiv) was dissolved in CH~2~Cl~2~ (2 mL). A solution of **15** (145 mg, 0.442 mmol) and DIPEA (150 μL, 2 equiv) in CH~2~Cl~2~ (2 mL) was added dropwise under ice-cooling. The mixture was allowed to warm to ambient temperature under stirring for 30 min. A solution of **10** (200 mg, 1.1 equiv) in CH~2~Cl~2~ (2 mL) was added, and stirring was continued for 90 min. The mixture was diluted with EtOAc (40 mL) and washed with water. The volatiles were removed under reduced pressure, the residue was taken up in EtOAc/hexane (1:1, 10 mL) and subjected to column chromatography (eluent: EtOAc/hexane (1:1), *R~f~* = 0.57). The protected intermediate was dissolved in MeOH (10 mL), and Pd/C-catalyst (30 mg) was added. The mixture was stirred vigorously under hydrogen. After completion of the hydrogenation, the solids were removed by filtration through celite, the volume was reduced on a rotary evaporator. The desired compound was purified via column chromatography (eluent: CH~2~Cl~2~/MeOH (10:0.5) → CH~2~Cl~2~/MeOH (10:0.6) + 1% AcOH). Removal of the volatiles under reduced pressure and by lyophilization afforded **18** as a white lyophilisate (221 mg, 74.1%). TLC (CH~2~Cl~2~/MeOH (10:0.6) + 0.5% AcOH): *R~f~* = 0.35. ^1^H NMR (400 MHz, methanol-*d*~4~): δ (ppm) 1.20 (s, 9H), 1.42 (s, 9H), 1.51--1.66 (m, 2H), 2.81--3.20 (m, 5H), 3.69 (br s, 1H), 4.21 (s, 1H), 4.35--4.60 (m, 3H), 6.79 (s, 2H), 7.04 (s, 2H), 7.24--7.35 (m, 2H), 7.39 (t, 2H, *J* 7.2 Hz), 7.54--7.73 (m, 2H), 7.80 (d, 2H, *J* 7.5 Hz). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for \[C~37~H~47~N~4~O~8~\]^+^: 675.3388, found: 675.3403. C~37~H~46~N~4~O~8~ (674.80).

### 4.3.4. {\[1-(9*H*-Fluoren-9-yl)-12,12-dimethyl-3,10-dioxo-2,11-dioxa-4,5,9-triazatridecan-5-yl\]carbonyl}-[l]{.smallcaps}-leucine (**19**) {#sec4.3.4}

Triphosgene (52.5 mg, 0.4 equiv) was dissolved in CH~2~Cl~2~ (2 mL). A solution of **16** (97.7 mg, 0.442 mmol) and DIPEA (150 μL, 2 equiv) in CH~2~Cl~2~ (2 mL) was added dropwise under ice-cooling. The mixture was allowed to warm to ambient temperature under stirring for 30 min. A solution of **10** (200 mg, 1.1 equiv) in CH~2~Cl~2~ (2 mL) was added and stirring was continued for 90 min. The mixture was diluted with EtOAc (40 mL) and washed with water. The volatiles were removed under reduced pressure and the residue was taken up in EtOAc/hexane (1:1, 10 mL) and subjected to column chromatography (eluent: EtOAc/hexane (1:1), *R~f~* = 0.71). The protected intermediate was dissolved in MeOH (10 mL), and Pd/C-catalyst (30 mg) was added. The mixture was stirred vigorously under hydrogen. After completion of the hydrogenation, the solids were removed by filtration through celite, and the volume was reduced on a rotary evaporator. The desired compound was purified via column chromatography (eluent: CH~2~Cl~2~/MeOH (10:0.4) → CH~2~Cl~2~/MeOH (10:0.6) + 0.1% TFA). Removal of the volatiles afforded **19** as a sticky solid (132 mg, 52.5%). TLC (CH~2~Cl~2~/MeOH (10:0.6) + 0.5% AcOH): *R~f~* = 0.55. ^1^H NMR (400 MHz, methanol-*d*~4~): δ (ppm) 0.90 (d, 6H, *J* 4.4 Hz), 1.42 (s, 9H), 1.52--1.77 (m, 5H), 3.03 (s, 2H), 3.35--3.95 (m, 2H), 4.23 (t, 1H, *J* 6.3 Hz), 4.29 (t, 1H, *J* 7.0 Hz), 4.52 (s, 2H), 7.31 (t, 2H, *J* 7.3 Hz), 7.39 (t, 2H, *J* 7.4 Hz), 7.59--7.71 (m, 2H), 7.79 (d, 2H, *J* 7.5 Hz). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for \[C~30~H~41~N~4~O~7~\]^+^: 569.2970, found: 569.2969. C~30~H~40~N~4~O~7~ (568.67).

### 4.3.5. Tyr(*t*Bu)-Arg(Pbf)-aza-Leu-Arg(Pbf)-Tyr(*t*Bu)-amide Hydrotrifluoroacetate (**21**) {#sec4.3.5}

Compound **21** was synthesized according to the general procedure (100 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 42:58--78:22, *t*~R~ = 14.9 min) afforded **21** as a white solid (39 mg, 42.6%). HRMS (ESI): *m*/*z* \[M + 2H\]^2+^ calcd for \[C~69~H~105~N~13~O~13~S~2~\]^2+^: 693.8693, found: 693.8708. C~69~H~103~N~13~O~13~S~2~·C~2~HF~3~O~2~ (1386.06 + 114.02).

### 4.3.6. Tyr(*t*Bu)-Arg(Pbf)-Leu-aza-Orn(Boc)-Tyr(*t*Bu)-amide Hydrotrifluoroacetate (**22**) {#sec4.3.6}

Compound **22** was synthesized according to the general procedure (100 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--20 min MeCN/0.1% aq TFA 42:58--78:22, *t*~R~ = 14.2 min) gave **22** as a white solid (42 mg, 52.7%). HRMS (ESI): *m*/*z* \[M + 2H\]^2+^ calcd for \[C~60~H~95~N~11~O~12~S\]^2+^: 596.8436, found: 596.8445. C~60~H~93~N~11~O~12~S·C~2~HF~3~O~2~ (1192.53 + 114.02).

### 4.3.7. Tyr(*t*Bu)-aza-Orn(Boc)-Leu-Arg(Pbf)-Tyr(*t*Bu)-amide Hydrotrifluoroacetate (**23**) {#sec4.3.7}

Compound **23** was synthesized according to the general procedure (100 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--20 min MeCN/0.1% aq TFA 42:58--78:22, *t*~R~ = 14.6 min) afforded **23** as a white solid (36 mg, 45.2%). HRMS (ESI): *m*/*z* \[M + 2H\]^2+^ calcd for \[C~60~H~95~N~11~O~12~S\]^2+^: 596.8436, found: 596.8446. C~60~H~93~N~11~O~12~S·C~2~HF~3~O~2~ (1192.53 + 114.02).

### 4.3.8. (2*R*,7*R*)-Diaminooctanedioyl-bis(Tyr-Arg-aza-Leu-Arg-Tyr-amide) Hexakis(hydrotrifluoroacetate) ((2*R*,7*R*)-**26**) {#sec4.3.8}

Compound **24** (2.08 mg, 5.1 μmol), HBTU (4.1 mg, 2.1 equiv), and HOBt (1.57 mg, 2 equiv) were dissolved in anhydrous DMF (400 μL). DIPEA (10 μL, 5 equiv) was added. Stirring was continued at rt for 5 min, followed by addition of a solution of **21** (19.3 mg, 12.8 μmol) in DMF. The mixture was stirred at 35 °C for 16 h. Water (10 mL) was added and the protected intermediate was extracted with CH~2~Cl~2~ (2 × 10 mL). The combined organic phases were concentrated, and the residue was dried in vacuo. TFA/water (95:5, 2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was added followed by lyophilization. The product was purified by preparative HPLC (gradient: 0--20 min: MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 15.6 min). Freeze-drying of the eluate gave (2*R*,7*R*)-**26** as a white fluffy solid (3.45 mg, 28.3%). HRMS (ESI): *m*/*z* \[M + 4H\]^4+^ calcd for \[C~78~H~126~N~28~O~16~\]^4+^: 427.7471, found: 427.7485. RP-HPLC (220 nm): 99% (*t*~R~ = 17.72 min, *k* = 5.2). C~78~H~122~N~28~O~16~·C~12~H~6~F~18~O~12~ (1708.01 + 684.12).

### 4.3.9. Octanedioyl-bis(Tyr-Arg-aza-Leu-Arg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (**27**) {#sec4.3.9}

Compound **21** (28.8 mg, 19.2 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 μL). Compound **25** (2.83 mg, 7.7 μmol) was added, and the mixture was stirred at 35 °C for 16 h. Water (10 mL) was added, and the protected intermediate was extracted with CH~2~Cl~2~ (2 × 10 mL). The combined extracts were evaporated, and the residue was dried in vacuo. TFA/water (95:5 v/v) (2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was added followed by lyophilization. The product was purified by preparative HPLC (gradient: 0--20 min: MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 16.5 min). Lyophilization of the eluate afforded **27** as a white fluffy solid (6.3 mg, 38.3%). HRMS (ESI): *m*/*z* \[M + 4H\]^4+^ calcd for C~78~H~124~N~26~O~16~: 420.2417, found: 420.2433. RP-HPLC (220 nm): 95% (*t*~R~ = 19.13 min, *k* = 5.7). C~78~H~120~N~26~O~16~·C~8~H~4~F~12~O~8~ (1677.98 + 456.08).

### 4.3.10. Octanedioyl-bis(Tyr-Arg-Leu-aza-Orn-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (**28**) {#sec4.3.10}

Compound **22** (16.7 mg, 12.8 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 μL). Compound **25** (1.9 mg, 5.1 μmol) was added, and the mixture was stirred at 35 °C for 16 h. After addition of water (10 mL), the protected intermediate was extracted with CH~2~Cl~2~ (2 × 10 mL). The combined extracts were evaporated, and the residue was dried in vacuo. TFA/water (95:5 v/v) (2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was added, followed by lyophilization. The product was purified by preparative HPLC (gradient: 0--20 min: MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 16.1 min). Lyophilization of the eluate afforded **28** as a white fluffy solid (4.2 mg, 40.2%). HRMS (ESI): *m*/*z* \[M + 4H\]^4+^ calcd for C~76~H~120~N~22~O~16~: 399.2308, found: 399.2327. RP-HPLC (220 nm): 99% (*t*~R~ = 19.55 min, *k* = 5.8). C~76~H~116~N~22~O~16~·C~8~H~4~F~12~O~8~ (1593.90 + 456.08).

### 4.3.11. Octanedioyl-bis(Tyr-Arg-Leu-aza-Arg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (**29**) {#sec4.3.11}

Compound **28** (3.7 mg, 2.05 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (300 μL). A solution of *N*,*N*′-di-Boc-1*H*-pyrazole-1-carboxamidine (1 mg/10 μL, 16 μL, 2.5 equiv) was added, and the mixture was stirred at rt for 4 h. After addition of water (5 mL), the protected intermediate was purified by preparative HPLC (gradient: 0--25 min: MeCN/0.1% aq TFA 3:97--52:48, *t*~R~ = 26.4 min). The eluates were subjected to lyophilization, and the residue was taken up in TFA/CH~2~Cl~2~/H~2~O (5:5:0.5, 3 mL). The resulting mixture was stirred for 3 h. The volatiles were removed on a rotary evaporator and by lyophilization. **29** was obtained as a white fluffy solid (1.62 mg, 37.0%). HRMS (ESI): *m*/*z* \[M + 4H\]^4+^ calcd for C~78~H~124~N~26~O~16~: 420.2417, found: 420.2434. RP-HPLC (220 nm): \>99% (*t*~R~ = 20.15 min, *k* = 6.0). C~78~H~120~N~26~O~16~·C~8~H~4~F~12~O~8~ (1677.98 + 456.08).

### 4.3.12. Octanedioyl-bis(Tyr-aza-Orn-Leu-Arg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (**30**) {#sec4.3.12}

Compound **23** (16.7 mg, 12.8 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 μL). Compound **25** (1.88 mg, 5.1 μmol) was added, and the mixture was stirred at 35 °C for 16 h. After addition of water (10 mL), the protected intermediate was extracted with CH~2~Cl~2~ (2 × 10 mL). The combined extracts were evaporated, and the residue was dried in vacuo. TFA/water (95:5 v/v) (2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was added followed by lyophilization. The product was purified by preparative HPLC (gradient: 0--20 min: MeCN/0.1% aq TFA 6:94--37:63, *t*~R~ = 17.4 min). Lyophilization of the eluate afforded **30** as a white fluffy solid (3.9 mg, 37.3%). HRMS (ESI): *m*/*z* \[M + 4H\]^4+^ calcd for C~76~H~120~N~22~O~16~: 399.2308, found: 399.2317. RP-HPLC (220 nm): 98% (*t*~R~ = 20.13 min, *k* = 6.0). C~76~H~116~N~22~O~16~·C~8~H~4~F~12~O~8~ (1593.90 + 456.08).

### 4.3.13. Octanedioyl-bis(Tyr-aza-Arg-Leu-Arg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (**31**) {#sec4.3.13}

Compound **30** (3.0 mg, 1.66 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (300 μL). A solution of *N*,*N*′-di-Boc-1*H*-pyrazole-1-carboxamidine (1 mg/10 μL, 13 μL, 2.5 equiv) was added, and the mixture was stirred at rt for 4 h. After addition of water (5 mL), the protected intermediate was purified by preparative HPLC (gradient: 0--25 min: MeCN/0.1% aq TFA 3:97--52:48, *t*~R~ = 26.1 min). The solvents were removed by lyophilization, the residue was taken up in TFA/CH~2~Cl~2~/H~2~O (5:5:0.5, 3 mL), and the resulting mixture was stirred for 3 h. The volatiles were removed on a rotary evaporator and by lyophilization. The title compound was obtained as a white fluffy solid (1.50 mg, 42.3%). HRMS (ESI): *m*/*z* \[M + 4H\]^4+^ calcd for C~78~H~124~N~26~O~16~: 420.2417, found: 420.2437. RP-HPLC (220 nm): 96% (*t*~R~ = 20.86 min, *k* = 6.3). C~78~H~120~N~26~O~16~·C~8~H~4~F~12~O~8~ (1677.98 + 456.08).

### 4.3.14. Octanoyl-Tyr-Arg-Leu-Arg-Tyr-amide Bis(hydrotrifluoroacetate) (**33**) {#sec4.3.14}

The pentapeptide **33** was synthesized according to the general procedure (82 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 22:78--51:49, *t*~R~ = 13.2 min) afforded **33** as a white solid (33.4 mg, 59.5%). HRMS (ESI): *m*/*z* \[M + 2H\]^2+^ calcd for \[C~44~H~72~N~12~O~8~\]^2+^: 448.2793, found: 448.2800. RP-HPLC (220 nm): 99% (*t*~R~ = 28.04 min, *k* = 8.8). C~44~H~70~N~12~O~8~·C~4~H~2~F~6~O~4~ (895.13 + 228.04).

### 4.3.15. Ac-Tyr-*N*^ω^-\[(4-aminobutyl)aminocarbonyl\]Arg-Leu-Arg-Tyr-amide Tris(hydrotrifluoroacetate) (**34**) {#sec4.3.15}

The pentapeptide **34** was synthesized according to the general procedure (18.8 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 14.4 min) gave **34** as a white solid (7.7 mg, 53.0%). HRMS (ESI): *m*/*z* \[M + 3H\]^3+^ calcd for \[C~43~H~71~N~14~O~9~\]^3+^: 309.1837, found: 309.1850. RP-HPLC (220 nm): 97% (*t*~R~ = 16.96 min, *k* = 4.9). C~43~H~68~N~14~O~9~·C~6~H~3~F~9~O~6~ (925.12 + 342.06).

### 4.3.16. Ac-Arg-Tyr-*N*^ω^-\[(4-aminobutyl)aminocarbonyl\]Arg-Leu-Arg-Tyr-amide Tetrakis(hydrotrifluoroacetate) (**35**) {#sec4.3.16}

The hexapeptide **35** was synthesized according to the general procedure (18.8 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 13.6 min) yielded **35** as a white solid (9.3 mg, 52.7%). HRMS (ESI): *m*/*z* \[M + 4H\]^4+^ calcd for \[C~49~H~84~N~18~O~10~\]^4+^: 271.1649, found: 217.1657. RP-HPLC (220 nm): 97% (*t*~R~ = 15.22 min, *k* = 4.3). C~49~H~80~N~18~O~10~·C~8~H~4~F~12~O~8~ (1081.31 + 456.08).

### 4.3.17. Ac-Arg-Tyr-Arg-Leu-Arg-Tyr-amide Tris(hydrotrifluoroacetate) (**36**) {#sec4.3.17}

The hexapeptide **36** was synthesized according to the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 13.7 min) afforded **36** as a white solid (18.3 mg, 65.5%). HRMS (ESI): *m*/*z* \[M + 3H\]^3+^ calcd for \[C~44~H~70~N~16~O~9~\]^3+^: 323.1910, found: 323.1927. RP-HPLC (220 nm): 99% (*t*~R~ = 15.98 min, *k* = 4.6). C~44~H~70~N~16~O~9~·C~6~H~3~F~9~O~6~ (967.15 + 342.06).

### 4.3.18. Ac-Arg-Tyr-Arg-Leu-*N*^ω^-\[(4-aminobutyl)aminocarbonyl\]Arg-Tyr-amide Tetrakis(hydrotrifluoroacetate) (**37**) {#sec4.3.18}

The hexapeptide **37** was synthesized according to the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 13.6 min) gave **37** as a white solid (7.2 mg, 21.9%). HRMS (ESI): *m*/*z* \[M + 3H\]^3+^ calcd for \[C~49~H~83~N~18~O~10~\]^3+^: 361.2174, found: 361.2187. RP-HPLC (220 nm): 99% (*t*~R~ = 15.17 min, *k* = 4.3). C~49~H~80~N~18~O~10~·C~8~H~4~F~12~O~8~ (1081.31 + 456.08).

### 4.3.19. Ac-Arg-Tyr-*N*^ω^-\[(4-aminobutyl)aminocarbonyl\]Arg-Leu-Arg-[d]{.smallcaps}-Tyr-amide Tetrakis(hydrotrifluoroacetate) (**38**) {#sec4.3.19}

The hexapeptide **38** was synthesized according to the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 13.6 min) afforded **38** as a white solid (5.7 mg, 17.4%). HRMS (ESI): *m*/*z* \[M + 4H\]^4+^ calcd for \[C~49~H~84~N~18~O~10~\]^4+^: 271.1649, found: 217.1666. RP-HPLC (220 nm): 98% (*t*~R~ = 15.25 min, *k* = 4.3). C~49~H~80~N~18~O~10~·C~8~H~4~F~12~O~8~ (1081.31 + 456.08).

### 4.3.20. Ac-Arg-Tyr-*N*^ω^-\[(4-aminobutyl)aminocarbonyl\]Arg-Leu-[d]{.smallcaps}-Arg-Tyr-amide Tetrakis(hydrotrifluoroacetate) (**39**) {#sec4.3.20}

The hexapeptide **39** was synthesized according to the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 13.3 min) yielded **39** as a white solid (6.0 mg, 18.3%). HRMS (ESI): *m*/*z* \[M + 3H\]^3+^ calcd for \[C~49~H~83~N~18~O~10~\]^3+^: 361.2174, found: 361.2190. RP-HPLC (220 nm): 95% (*t*~R~ = 14.77 min, *k* = 4.1). C~49~H~80~N~18~O~10~·C~8~H~4~F~12~O~8~ (1081.31 + 456.08).

### 4.3.21. Ac-Arg-Tyr-*N*^ω^-\[(4-aminobutyl)aminocarbonyl\]Arg-[d]{.smallcaps}-Leu-Arg-Tyr-amide Tetrakis(hydrotrifluoroacetate) (**40**) {#sec4.3.21}

The hexapeptide **40** was synthesized according to the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 13.4 min) afforded **40** as a white solid (6.6 mg, 20.1%). HRMS (ESI): *m*/*z* \[M + 3H\]^3+^ calcd for \[C~49~H~83~N~18~O~10~\]^3+^: 361.2174, found: 361.2189. RP-HPLC (220 nm): 96% (*t*~R~ = 14.33 min, *k* = 4.0). C~49~H~80~N~18~O~10~·C~8~H~4~F~12~O~8~ (1081.31 + 456.08).

### 4.3.22. Ac-Arg-[d]{.smallcaps}-Tyr-{*N*^ω^-\[*N*-(4-aminobutyl)aminocarbonyl\]}Arg-Leu-Arg-Tyr-amide Tetrakis(hydrotrifluoroacetate) (**41**) {#sec4.3.22}

The hexapeptide **41** was synthesized according to the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 13.5 min) gave **41** as a white solid (6.7 mg, 20.5%). HRMS (ESI): *m*/*z* \[M + 3H\]^3+^ calcd for \[C~49~H~83~N~18~O~10~\]^3+^: 361.2174, found: 361.2190. RP-HPLC (220 nm): 95% (*t*~R~ = 15.1 min, *k* = 4.3). C~49~H~80~N~18~O~10~·C~8~H~4~F~12~O~8~ (1081.31 + 456.08).

### 4.3.23. Ac-[d]{.smallcaps}-Arg-Tyr-{*N*^ω^-\[*N*-(4-aminobutyl)aminocarbonyl\]}Arg-Leu-Arg-Tyr-amide Tetrakis(hydrotrifluoroacetate) (**42**) {#sec4.3.23}

The hexapeptide **42** was synthesized according to the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 13.5 min) afforded **42** as a white solid (7.0 mg, 21.4%). HRMS (ESI): *m*/*z* \[M + 3H\]^3+^ calcd for \[C~49~H~83~N~18~O~10~\]^3+^: 361.2174, found: 361.2190. RP-HPLC (220 nm): 99% (*t*~R~ = 14.94 min, *k* = 4.2). C~49~H~80~N~18~O~10~·C~8~H~4~F~12~O~8~ (1081.31 + 456.08).

### 4.3.24. Ac-Arg-Tyr-{*N*^ω^-\[*N*-(4-aminobutyl)aminocarbonyl\]}Arg-Leu-Arg-Tyr-OH Tetrakis(hydrotrifluoroacetate) (**43**) {#sec4.3.24}

The hexapeptide **43** was synthesized according to the general procedure (44.1 mg, H-[l]{.smallcaps}-Tyr(*t*Bu)-2CT resin (loading: 0.68 mmol/g)). Purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 13:87--42:58, *t*~R~ = 10.7 min) yielded **43** as a white solid (15.2 mg, 32.9%). HRMS (ESI): *m*/*z* \[M + 4H\]^4+^ calcd for \[C~49~H~83~N~17~O~11~\]^4+^: 271.4109, found: 271.4124. RP-HPLC (220 nm): 95% (*t*~R~ = 16.28 min, *k* = 4.7). C~49~H~79~N~17~O~11~·C~8~H~4~F~12~O~8~ (1082.28 + 456.08).

### 4.3.25. (*S*)-2-Acetamido-*N*-((*S*)-1-{\[(12*S*,15*S*,18*S*,21*S*)-2-amino-15-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-18-isobutyl-4,11,14,17,20-pentaoxo-1,3,5,10,13,16,19-heptaazacyclotetracos-2-en-21-yl\]amino}-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide Tris(hydrotrifluoroacetate) (**44**) {#sec4.3.25}

Compound **43** (9.0 mg, 5.85 μmol), HOBt (1.79 mg, 2 equiv), and DIPEA (0.9 μL, 8 equiv) were dissolved in anhydrous DMF (5850 μL) to give a 1 mM solution. A solution of PyBOP (3.65 mg, 1.2 equiv) was added dropwise. After stirring at rt for 24 h, 0.1% aq TFA (20 mL) was added, and purification by preparative HPLC (gradient: 0--18 min MeCN/0.1% aq TFA 3:97--42:58, *t*~R~ = 15.9 min) afforded **44** as a white solid (3.9 mg, 47.4%). HRMS (ESI): *m*/*z* \[M + 3H\]^3+^ calcd for \[C~49~H~80~N~17~O~10~\]^3+^: 355.5419, found: 355.5434. RP-HPLC (220 nm): 95% (*t*~R~ = 18.4 min, *k* = 5.4). C~49~H~77~N~17~O~10~·C~6~H~3~F~9~O~6~ (1064.27 + 342.06).

4.4. Cells {#sec4.4}
----------

HEC-1B (HTB-113) human endometrial cancer cells were from the American Type Culture Collection (Rockville, MD). MCF-7-Y~1~ cells were previously established in our laboratory.^[@ref23]^ HEL cells were kindly provided by Dr. M. C. Michel (Universitätsklinikum Essen, Germany), and CHO-K1 (ACC-110) cells and HEK293T (ACC 635) cells were from Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany).

Routinely performed examinations for mycoplasma contamination using the Venor GeM Mycoplasma Detection Kit (Minerva Biolabs, Berlin, Germany) were negative for all cell types.

### 4.4.1. HEK293T-ARRB1-hY~4~R and HEK293T-ARRB2-hY~4~R Cells {#sec4.4.1}

The β-arrestin recruitment was quantified by a luciferase complementation assay based on the emerald luciferase (ELuc) from the brazilian click-beetle *Pyrearinus termitilluminans*. The fusion construct of the human hY~4~R (the hY~4~R cDNA was from cDNA Resource Center, Bloomsburg, PA) and the C-terminal luciferase fragment (hY~4~R-ELucC) was generated using the previously described construct SSTR2-ELucC^[@ref31],[@ref32]^ by replacing the cDNA of SSTR2 with the cDNA of the hY~4~R. HEK293T cells were stably transfected with the pcDNA3.1/myc-HIS (B) vector encoding the β-arrestin isoform 1 or 2, N-terminally fused with the N-terminus of the luciferase (ELucN-ARRB1 or ELucN-ARRB2, respectively)^[@ref31]^ and the pcDNA4/V5-HIS (B) vector encoding hY~4~R-ELucC using G418 (600 μg/mL) and zeocin (40 μg/mL) as selection antibiotics, as previously described for the H~1~R.^[@ref33]^ To determine the hY~4~R-ELucC expression, saturation binding studies were performed with both HEK293T-ARRB1-hY~4~R cells and HEK293T-ARRB2-hY~4~R cells using the radioligand **45** (cf. [SI Figures S6 and S7](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00451/suppl_file/ao7b00451_si_001.pdf)).

4.5. Cell Culture {#sec4.5}
-----------------

Cells were maintained in 25 or 75 cm^2^ flasks (Sarstedt, Nümbrecht, Germany) in a humidified atmosphere (95% air, 5% CO~2~) at 37 °C. MCF-7-Y~1~ cells,^[@ref22]^ HEL cells,^[@ref34]^ CHO-hY~2~-G~qi5~-mtAEQ cells,^[@ref26]^ CHO-hY~4~-G~qi5~-mtAEQ cells,^[@ref26]^ and HEK293T-hY~4~R-CRE Luc cells^[@ref11]^ were cultured as described previously. HEK293T-ARRB1-hY~4~R and HEK293T-ARRB2-hY~4~R cells were maintained in Dulbecco's modified Eagle's medium containing 10% FCS, 600 μg/mL G418, and 40 μg/mL zeocin.

4.6. Radioligand Binding Assays {#sec4.6}
-------------------------------

Radioligand binding assays at all NPY receptor subtypes were performed at 22 ± 1 °C according to the experimental protocols described in detail previously.^[@ref11]^ Radioactivity (dpm) was measured with a MicroBeta2 plate counter (PerkinElmer, Rodgau, Germany). Cells, buffers, radioligands, and the respective *K*~d~ values and concentrations, as well as the assay conditions are summarized in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}.

###### Conditions of the Radioligand Competitions Binding Assays at the NPY Receptor Subtypes

                           Y~1~R                                                                                                                           Y~2~R                                                      Y~4~R                                                      Y~5~R
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------------------
  receptor source          MCF-7-Y~1~ cells^[@ref23]^                                                                                                      CHO-hY~2~R-G~qi5~-mtAEQ cells^[@ref25]^                    CHO-hY~4~R-G~qi5~-mtAEQ cells^[@ref26]^                    HEC-1B-hY~5~ cells^[@ref27]^
  buffer                   *N*-(2-hydroxyethyl)piperazine-*N*′-ethanesulfonic acid (HEPES) buffer containing 150 mM NaCl[a](#t3fn1){ref-type="table-fn"}   sodium-free HEPES buffer[b](#t3fn2){ref-type="table-fn"}   sodium-free HEPES buffer[b](#t3fn2){ref-type="table-fn"}   HEPES buffer containing 150 mM NaCl[a](#t3fn1){ref-type="table-fn"}
  radioligand              compd **46**                                                                                                                    \[^3^H\]propionyl-pNPY                                     compd **45**([@ref11])                                     \[^3^H\]propionyl-pNPY
  *K*~d~                   6.2 nM                                                                                                                          1.4 nM                                                     0.67 nM                                                    4.8 nM
  concentration            4 nM                                                                                                                            1.0 nM                                                     0.6 nM                                                     4 nM
  incubation period        90 min                                                                                                                          90 min                                                     90 min                                                     120 min
  separation               suction                                                                                                                         suction                                                    filtration                                                 suction
  scintillation cocktail   Optiphase Supermix                                                                                                              Optiphase Supermix                                         Rotiscint eco plus                                         Optiphase Supermix

Isotonic HEPES buffer pH 7.4 (150 mM NaCl, 10 mM HEPES, 25 mM NaHCO~3~, 2.5 mM CaCl~2~, 1.2 mM KH~2~PO~4~, 1.2 mM MgSO~4~, 5 mM KCl).

Hypotonic, sodium-free HEPES buffer pH 7.4 (25 mM HEPES, 2.5 mM CaCl~2~, 1 mM MgCl~2~). Binding buffers were supplemented with BSA (1%) and bacitracin (0.1 mg/mL).

4.7. Fura-2 Calcium Assay {#sec4.7}
-------------------------

The assay was performed with HEL cells as previously described.^[@ref34],[@ref35]^

4.8. Aequorin Calcium Assay {#sec4.8}
---------------------------

The assay was performed on CHO-hY~4~-G~qi5~-mtAEQ cells as previously described^[@ref26]^ using a GENios Pro plate reader (Tecan, Salzburg, Austria). Areas under the curve were calculated using SigmaPlot 12.5 software (Systat Software Inc., Chicago, IL).

4.9. Luciferase Assay {#sec4.9}
---------------------

The Luciferase assay was performed on HEK293-hY~4~-CRE Luc cells as previously described.^[@ref11]^

4.10. β-Arrestin Recruitment Assay {#sec4.10}
----------------------------------

The recruitment of β-arrestin was measured via the split-luciferase complementation technique.^[@ref32]^ Agonist potencies were determined on HEK293T-ARRB1-Y~4~R and HEK293T-ARRB2-Y~4~R cells using the GENios Pro microplate reader (Tecan, Salzburg, Austria) as previously described for HEK293T-ARRB1-H~1~R and HEK293T-ARRB2-H~2~R, respectively.^[@ref33]^ For the determination of antagonism, the cells were preincubated in the presence of the antagonist for 15 min. Ten microliters of an hPP solution (30 nM, final concentration 3 nM) was added and incubation was continued at 25 °C for 60 min. The plates were further processed as in the case of the agonist mode.

4.11. Data Analysis {#sec4.11}
-------------------

Concentration response curves from functional assays and displacement curves from radioligand competition binding were analyzed by four-parameter sigmoidal fits (GraphPad Prism 5.0, San Diego, CA). Agonist potencies are given as EC~50~ values, intrinsic activities are expressed as α values with respect to the effect of 1 μM hPP (maximal response α = 1.0). Antagonistic activities were determined in the presence of 3 nM hPP (β-arrestin 1/2 assay, EC~50~ = 3.54 nM (ARRB1), EC~50~ = 2.74 nM (ARRB2)), 100 nM hPP (aequorin assay, EC~50~ = 9.7 nM) or 10 nM pNPY (Fura-2 Ca^2+^ assay, EC~50~ = 0.87 nM (Y~1~R)). *K*~i~ and *K*~b~ (Fura-2 Ca^2+^ (Y~1~R)) values were calculated from IC~50~ values using the Cheng--Prusoff equation.^[@ref36]^
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br s

:   broad singlet

CHO

:   Chinese hamster ovary

DEA

:   diethylamine

DIPEA

:   *N*,*N*-diisopropylethylamine

EtOAc

:   ethyl acetate

FCS

:   fetal calf serum

H~2~

:   hydrogen gas

HATU

:   1-\[bis(dimethylamino)methylene\]-1*H*-1,2,3-triazolo\[4,5-*b*\]pyridinium 3-oxid hexafluorophosphate

HBTU

:   3-\[bis(dimethylamino)methyliumyl\]-3*H*-benzotriazol-1-oxide hexafluorophosphate

HEC

:   human endometrial cancer

HEL

:   human erythroleukemia cell line

HEPES

:   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HOBt

:   hydroxybenzotriazole

hPP

:   human pancreatic polypeptide

*K*~b~

:   inhibition constant

MCF-7

:   Michigan cancer foundation

MeCN

:   acetonitrile

MeOH

:   methanol

Orn

:   ornithine

OSu

:   succinimidyl ester

Pbf

:   2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl

pNPY

:   porcine neuropeptide Y

PyBOP

:   benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate

PYY

:   peptide YY

RLU

:   relative light unit

RP

:   reversed phase

SPPS

:   solid phase peptide synthesis

TEA

:   triethylamine

Y~1,2,4,5~R

:   NPY Y~1,2,4,5~ receptor
